



Cell-Free Glycoengineering of the Recombinant SARS-CoV-2 Spike Glycoprotein

Johannes Ruhnau^{1†}, Valerian Grote^{1†}, Mariana Juarez-Osorio¹, Dunja Bruder^{2,3}, Reza Mahour¹, Erdmann Rapp^{1,4}, Thomas F. T. Rexer^{1*} and Udo Reichl^{1,5}

¹Max Planck Institute for Dynamics of Complex Technical Systems, Bioprocess Engineering, Magdeburg, Germany, ²Infection Immunology, Institute of Medical Microbiology, Infection Prevention and Control, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke University Magdeburg, Magdeburg, Germany, ³Immune Regulation Group, Helmholtz Centre for Infection Research, Braunschweig, Germany, ⁴glyXera GmbH, Magdeburg, Germany, ⁵Otto-von-Guericke University Magdeburg, Chair of Bioprocess Engineering, Magdeburg, Germany

OPEN ACCESS

Edited by:

Dong-Yup Lee,
Sungkyunkwan University,
South Korea

Reviewed by:

Dong-Myung Kim,
Chungnam National University,
South Korea
Alexander D. Frey,
Aalto University, Finland

*Correspondence:

Thomas F. T. Rexer
rexer@mpi-magdeburg.mpg.de

[†]These authors share first authorship

Specialty section:

This article was submitted to
Synthetic Biology,
a section of the journal
Frontiers in Bioengineering and
Biotechnology

Received: 22 April 2021

Accepted: 15 July 2021

Published: 16 August 2021

Citation:

Ruhnau J, Grote V, Juarez-Osorio M, Bruder D, Mahour R, Rapp E, Rexer T and Reichl U (2021) Cell-Free Glycoengineering of the Recombinant SARS-CoV-2 Spike Glycoprotein. *Front. Bioeng. Biotechnol.* 9:699025. doi: 10.3389/fbioe.2021.699025

The baculovirus-insect cell expression system is readily utilized to produce viral glycoproteins for research as well as for subunit vaccines and vaccine candidates, for instance against SARS-CoV-2 infections. However, the glycoforms of recombinant proteins derived from this expression system are inherently different from mammalian cell-derived glycoforms with mainly complex-type *N*-glycans attached, and the impact of these differences in protein glycosylation on the immunogenicity is severely under investigated. This applies also to the SARS-CoV-2 spike glycoprotein, which is the antigen target of all licensed vaccines and vaccine candidates including virus like particles and subunit vaccines that are variants of the spike protein. Here, we expressed the transmembrane-deleted human β -1,2 *N*-acetylglucosamintransferases I and II (MGAT1 Δ TM and MGAT2 Δ TM) and the β -1,4-galactosyltransferase (GalT Δ TM) in *E. coli* to *in-vitro* remodel the *N*-glycans of a recombinant SARS-CoV-2 spike glycoprotein derived from insect cells. In a cell-free sequential one-pot reaction, fucosylated and afucosylated paucimannose-type *N*-glycans were converted to complex-type galactosylated *N*-glycans. In the future, this *in-vitro* glycoengineering approach can be used to efficiently generate a wide range of *N*-glycans on antigens considered as vaccine candidates for animal trials and preclinical testing to better characterize the impact of *N*-glycosylation on immunity and to improve the efficacy of protein subunit vaccines.

Keywords: SARS-CoV-2, COVID- 19, glycoengineering, subunit vaccine, cell-free synthetic biology

Abbreviations: APTS, 8-Aminopyrene-1,3,6-trisulfonic acid; dH₂O, Deionized water; GlcNAc, *N*-acetylglucosamine; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HILIC, Hydrophilic interaction liquid chromatography; His tag, Histidine tag; IMAC, Immobilized metal affinity chromatography; IPTG, Isopropyl β -D-1-thiogalactopyranoside; LC, Liquid chromatography; MALDI-TOF, Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; MS, Mass spectrometry; MnCl₂, Mangan(II)-chlorid; MTU, Migration Time Units after alignment to internal standards; rpm, Rounds per min; SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis; SPE, Solid phase extraction; TPH, Total peak height; UDP-galactose, Uridine-diphosphate galactose; UDP-GlcNAc, Uridine diphosphate *N*-acetylglucosamine; xCGE-LIF, Multiplexed capillary gel electrophoresis with laser-induced fluorescence detection.

INTRODUCTION

Most epidemics caused by viral infections that are associated with a significant death toll were caused by enveloped viruses such as influenza A virus, human immunodeficiency virus (HIV), Zika virus, Yellow fever virus, Dengue virus and Ebolavirus. Often, the main target for neutralizing antibodies to evoke a strong immune response is a glycosylated envelope membrane protein. Thus, in the development of vaccines, glycoproteins are typically in the focus of interest. In general, the glycosylation of proteins plays a critical role regarding structure, function, solubility, stability, trafficking, and ligand-binding (Imperiali and O’connor, 1999; Dalziel et al., 2014;

Varki, 2017). Furthermore, glycosylation plays a major role for pharmacokinetics and pharmacodynamics of biologics and for pathogen-host interaction (Bagdonaite and Wandall, 2018; Cymer et al., 2018; Watanabe et al., 2019). In viral pathogenesis, glycosylation affects the attachment and release of virus particles as well as immune evasion (Bagdonaite and Wandall, 2018; Watanabe et al., 2019; Schön et al., 2020). Especially the latter is a major hurdle for vaccine design. The mode of actions that are known to be employed to invade the immune system are secretion and shedding of glycoproteins that function as a decoy to the immune system, and the shielding of epitopes (Watanabe et al., 2019). The latter is facilitated by occluding antigenic epitopes with

TABLE 1 | N-glycan categories and nomenclature for all detected and referenced structures with the exception of oligomannose-type N-glycans. The monosaccharide building blocks are mannose (green circle), GlcNAc (blue square), fucose (red triangle) and galactose (yellow circle).

Category	Structure	Diagram	Structure	Diagram
Paucimannose-type	Man2F			
	Man3		Man3F	
Hybrid-type	G0-Gn (3)		G0F-Gn (3)	
	G1F-Gn (3)			
Complex-type	G0		G0F	
	G2		G2F	

host-derived glycans that are obtained through hijacking the host's cellular glycosylation machinery (Schwarzer et al., 2009; Francica et al., 2010; Helle et al., 2011; Rödig et al., 2011; Rödig et al., 2013; Sommerstein et al., 2015; Behrens et al., 2016; Gram et al., 2016; Walls et al., 2016; Pralow et al., 2021). Moreover, it has been shown that also the glycoform itself can have an impact on binding and transmission assay as well as on transmissibility, antigenicity, and immunogenicity in animal models (Lin et al., 2003; Hütter et al., 2013; Chen et al., 2014; Li et al., 2016; Go et al., 2017). While it is assumed that immunogenic antigens benefit from mimicking the glycosylation of host cell proteins, it has also been proposed that modification of specific terminal sugar residues could be used to amplify vaccine efficacy (Galili, 2020; Chen, 2021). However, due to the complexity of protein glycosylation and the prevailing lack of methods to introduce defined modifications in the glycan composition of the proteins of interest, the topic is under investigated (Watanabe et al., 2019; Grant et al., 2020; Schön et al., 2020).

The ongoing corona virus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—a single-stranded, positive-sense RNA virus (Walls et al., 2020). Its membrane envelope consists of three membrane proteins: the surface spike (S) glycoprotein, an integral membrane protein and an envelope protein (Wan et al., 2020; Zhou et al., 2020). Virus entry into human host cells is mediated by the S glycoprotein that binds to angiotensin-converting enzyme 2 (Walls et al., 2020). The S protein has 22 N-linked glycosylation sites. Thus, it is significantly more glycosylated than, for instance, the influenza A hemagglutinin (Wrapp et al., 2020). For the SARS-CoV-1 spike protein it has been shown previously that N-glycans significantly impact antibody response and neutralizing antibody levels (Chen et al., 2014; Walls et al., 2020).

For the investigation of the impact of glycoforms on the immunogenicity, mainly animal cell lines such as HEK and CHO cells that produce differentially glycosylated proteins are employed (Lin et al., 2013; Schön et al., 2020). However, due to need to develop specific expression protocols for each cell line, this approach is highly work-intensive. Additionally, the inherent macro- and microheterogeneity of glycoproteins complicate the elucidation of the role of specific glycans in, for instance, regarding their immunogenicity in animal models.

Over the past years the establishment of protocols for expression of eukaryotic and bacterial glycosyltransferases has facilitated the processing of glycans in cell-free one-pot reactions. As a platform technology, the corresponding *in-vitro* glycoengineering approaches have the potential to tailor the glycoform of proteins independent of the expression systems used (Van Landuyt et al., 2019; Rexer et al., 2020a). In our study, recombinant human β -1,2 N-acetylglucosaminyltransferases I and II (MGAT1 Δ TM and MGAT2 Δ TM) and β -1,4-galactosyltransferase (GalT Δ TM) expressed in *E. coli* were utilized to convert insect cell-derived paucimannose structures of recombinant SARS-CoV-2 spike glycoprotein to typical mammalian, complex-type galactosylated structures in a cell-free one-pot reaction (Fujiyama et al., 2001; Boeggeman et al., 2003; Bendiak, 2014; Ramakrishnan and Qasba, 2014; Stanley, 2014). Glycan structures were analyzed using multiplexed capillary gel electrophoresis with laser-induced fluorescence detection (xCGE-LIF) and Matrix-assisted laser

desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Results obtained clearly demonstrate that a large fraction of fucosylated and afucosylated, Man3-glycans were transferred to biantennary G2 and G2F structures (also **Table 1**).

MATERIALS AND METHODS

Enzymes

SARS-CoV-2 spike protein containing the S1 subunit and the S2 subunit ectodomain was purchased from SinoBiologica (Beijing, PR China). The recombinant protein was produced using the baculovirus-insect-cell expression system using High-Five™ cells. The protein bears a C-terminal His-tag. For all other materials see supporting information (SI).

Gene Expression


Genes encoding for the trans-membrane deleted (Δ TM) variants of *Homo sapiens* α -1,3-mannosyl-glycoprotein 2- β -N-acetylglucosaminyltransferase (MGAT1 Δ TM) (E.C. 2.4.1.201), α -1,6-mannosyl-glycoprotein 2- β -N-acetylglucosaminyltransferase (MGAT2 Δ TM) (E.C. 2.4.1.143) and β -N-acetylglucosaminylglycopeptide β -1,4-galactosyltransferase (GalT Δ TM) (E.C. 2.4.1.38) were expressed in *E. coli*. All constructs are bearing a 6 x histidine-tag (His-tag). For information on the cultivation, strains and vectors used **Supplementary Material**.

Purification by Ion Metal Affinity Chromatography

E. coli cells were lysed at 4°C by high-pressure cell disruption (3 cycles, 400–600 bar) using an HPL6 homogenizer (Maximator GmbH, Nordhausen, Germany) followed by centrifugation at 7,200 \times g for 20 min at 4°C to precipitate cell debris. The overexpressed enzymes were filtered through 8 μ m syringe filters and then purified by ion metal chromatography using an ÄKTA™ start system equipped with HisTrap™ HP columns (1 ml) (both GE Healthcare Life Sciences, Little Chalfont, United Kingdom). A buffer exchange was carried out to remove excess imidazole using an Amicon® Ultra-15 Centrifugal Filter Unit—3 kDa MW cutoff (UFC900308, Darmstadt, Germany) using standard procedures. Enzymes were stored in 50% (v/v) glycerol stock solutions at -20°C. Enzyme concentrations were determined by performing a bicinchoninic acid (BCA) assay using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific; Waltham, United States).

One-Pot *In-Vitro* Glycoengineering Reactions

Reactions were performed by sequential addition of enzymes in buffered (25 mM HEPES, pH 6.5) aqueous solutions supplemented with 10 mM MnCl₂ at 37°C under shaking (550 rpm). The initial reaction volume (1 ml) contained 0.1 μ g/ml of SARS-CoV-2 spike protein, 4 mM UDP-GlcNAc and 0.2 μ g/ μ L MGAT1 Δ TM. After a reaction time of 12 h, 150 μ L of a buffered solution containing 4 mM UDP-GlcNAc and



0.85 $\mu\text{g}/\mu\text{L}$ MGAT2 ΔTM was added to 500 μL of the reaction. After 12 more hours, 175 μL of a buffered solution containing 4 mM UDP-galactose and 0.56 $\mu\text{g}/\mu\text{L}$ GalT ΔTM was added to 325 μL of the reaction mix. Three aliquots of the reactions were taken for *N*-glycan analysis by xCGE-LIF before the addition of each enzyme and at the end of the reaction (12 h after GalT ΔTM addition).

Sample Pre-treatment: PNGase F Digest of N-Glycosylated Proteins

Samples from *in-vitro* glycoengineering reactions were vacuum evaporated. At least 1 μg *N*-glycosylated protein sample was linearized and denatured by adding 2 μL 2% (w/v) SDS in PBS buffer (pH 7.2) and subsequent heating at 60°C for 10 min. Samples were cooled down to room temperature. 4 μL 8% (w/v) IGEPAL in PBS and 1 μL of a 1 U/ μL PNGase F solution were added. Samples were incubated for 1 h at 37°C, vacuum evaporated and dissolved in 20 μL LC-MS grade H₂O.

Multiplexed Capillary Gel Electrophoresis With Laser-Induced Fluorescence Detection Based N-Glycan Analysis

N-glycan analysis based on xCGE-LIF was conducted using a glyXboxCE™-system (glyXera, Magdeburg, Germany) according to (Hennig et al., 2015; Hennig et al., 2016). Briefly, 2 μL of each

sample was used for fluorescent labelling of *N*-glycans with 8-aminopyrene-1,3,6-trisulfonic acid (APTS) following post derivatization clean-up by hydrophilic interaction liquid chromatography-solid phase extraction (HILIC-SPE) with the glyXprep16™ kit (glyXera). Data processing, normalization of migration times and annotation of *N*-glycan fingerprints were performed with glyXtool™ software (glyXera).

Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Based N-Glycan Analysis

MALDI-TOF-MS analysis of released *N*-glycans was performed as described previously (Selman et al., 2011; Fischöder et al., 2019). Briefly, 0.9 cm cotton rope was used for Cotton HILIC SPE. The stationary phase was equilibrated with 50 μL LC-MS grade H₂O followed by 50 μL 85% ACN_{aq}. 10 μL of released *N*-glycans were adjusted to 70 μL 85% ACN_{aq} with 1% TFA and loaded onto the HILIC phase. Following two washing steps with 50 μL 85% ACN_{aq} with 1% TFA and 50 μL 85% ACN_{aq}, the samples were eluted in 70 μL LC-MS grade H₂O, vacuum evaporated and dissolved in 20 μL LC-MS grade H₂O. For the MALDI-TOF-MS analysis 0.5 μL super-dihydroxybenzoic acid (S-DHB) ($\geq 99.0\%$, Sigma-Aldrich, Steinheim, Germany) matrix (10 mg/ml) in 30% (v/v) ACN_{aq}, 0.1% (v/v) TFA, 2 mM NaCl was spotted onto a MTP AnchorChip 800/384 TF MALDI target




FIGURE 2 | xCGE-LIF *N*-glycan fingerprints of unprocessed and *in-vitro* glycoengineered SARS-CoV-2 spike protein *N*-glycans. *N*-glycosylation pattern of the spike protein: **(A)** unprocessed (blue) and 12 h after start of the reaction with MGAT1ΔTM (red); **(B)** 12 h after start of the reaction with MGAT1ΔTM (blue) and 12 h after the addition of MGAT2ΔTM (red); **(C)** 12 h after the addition of MGAT2ΔTM (blue) and 12 h after addition of GalTΔTM (red). TPH, total peak height.

(Bruker Daltonics, Bremen, Germany). Subsequently 1 μ L sample was applied onto the dried matrix layer. Measurements were carried out on an ultrafleXtreme MALDI-TOF/TOF MS (Bruker Daltonics, Bremen, Germany) in reflectron positive ion mode. Data was processed with the top-hat filter and the adjacent-averaging algorithm using flexAnalysis version 3.3 Build 80 (Bruker Daltonics, Bremen, Germany).

N-Glycan Nomenclature


N-Glycan nomenclature was adopted from Stanley et al. (2015). Depiction of *N*-glycan structures followed the Symbol Nomenclature for Glycans (SNFG) guidelines (Neelamegham et al., 2019). The *N*-glycan sketches in this manuscript were

produced using the “Glycan Builder2” software tool (Tsuchiya et al., 2017). *N*-Glycans are typically categorized into paucimannose-, oligomannose-, hybrid- and complex-type structures.

RESULTS

Pathway Design

The human *in-vivo* cascade reaction for the generation of complex-type *N*-glycans from the conserved ER-derived oligomannose-type *N*-glycan precursor $\text{GlcNAc}_2\text{Man}_9\text{Glc}_3$, was in part re-modelled *in-vitro* to generate fully galactosylated



complex-type *N*-glycans starting from insect cell-derived paucimannose-type *N*-glycans. Central to the construction of the simplified *in-vitro* cascade is the ability of human MGAT1

to utilize Man3 and Man3F as substrates, which allows circumventing the application of recombinant mannosidases (**Figure 1**). For the production of the G2 structure from

paucimannose-type *N*-glycans, the three recombinant glycosyltransferases MGAT1 Δ TM, MGAT2 Δ TM and GalT Δ TM were successfully produced in *E. coli* (**Supplementary Material**). Enzyme concentrations of typically 1.3 mg/ml after ion metal affinity chromatography (IMAC) and buffer exchange were obtained. In scouting experiments, it was confirmed that all enzymes are active in the buffered solutions (pH 6.5) with MnCl₂ supplemented as a co-factor (data not shown).

Glycoform of the Unprocessed Recombinant SARS-CoV-2 Spike Glycoprotein

Analytical characterization of the unprocessed and glycoengineered SARS-CoV 2 spike protein was achieved by the two orthogonal methods xCGE-LIF and MALDI-TOF-MS (**Figure 2** and **Figure 3**). The high-resolution *N*-glycan fingerprints (migration time aligned and peak height normalized electropherograms) from xCGE-LIF combined with the precise mass profiles generated by MALDI-TOF-MS allowed for fast and robust annotation also of isomeric *N*-glycan structures. Furthermore, normalization of *N*-glycan fingerprints to total peak height enabled relative quantification of individual *N*-glycan structures by xCGE-LIF. The glycans released by PNGase F from the insect-cell-produced recombinant SARS-CoV-2 spike glycoprotein are mainly α -1,6-core-fucosylated Man3F and G0F-Gn (3) structures (**Figure 2A** blue and **Figure 3A**). Moreover, Man2F, Man3, the hybrid-type structure G0-Gn (3), the complex-type structure G0F, and afucosylated oligomannose-type structures were detected. There is excellent agreement between xCGE-LIF and MALDI-TOF-MS measurements.

In-vitro Glycoengineering of SARS-CoV-2 Spike Glycoprotein

Recombinant MGAT1 Δ TM, MGAT2 Δ TM and GalT Δ TM were used in a one-pot glycoengineering reaction to convert the paucimannose structures to complex-type *N*-glycans. In scouting experiments it was found that after MGAT1 Δ TM, MGAT2 Δ TM and GalT Δ TM addition at the start of the reaction, Man3F was converted to, at least in parts, to the hybrid-type structure G1F-Gn (3) missing the extension on the α 1-6 mannosylated antenna catalysed by MGAT2. G1F-Gn (3) is not a natural substrate for MGAT2 and can, if at all, most likely only be processed at very low turnover rates. Thus, the reactions were carried out by adding the enzymes sequentially as detailed in M&M. In the first step, a GlcNAc residue is added from UDP-GlcNAc to the α -1,3-linked terminal mannose antenna of Man3F and Man3 by MGAT1 Δ TM (**Figure 2A** and **Figures 3A,B**). After a reaction time of 12 h 24.7% of Man3 and 32% Man3F were converted to G0-Gn (3) and G0F-Gn (3), respectively. Scouting experiment showed that the conversion is typically irreversible and, thus, the incomplete processing is either due to low turnover or possible enzyme inactivation of MGAT1 Δ TM. Another possibility is that the

glycans are inaccessible for MGAT1 Δ TM but can be released from the backbone by PNGase F. In the second step, UDP-GlcNAc and MGAT2 Δ TM are added. After incubation for 12 h, the hybrid-type structures G0-Gn (3) and G0F-Gn (3) were converted to G0 and G0F with conversion rates of 100 and 85.2%, respectively (**Figure 2B** and **Figure 3C**). MGAT2 Δ TM did not show any activity towards Man3 and Man3F. However, as mentioned before, this could be due the inaccessibility of these glycans. In the final step, the reaction was supplemented with UDP-galactose and GalT Δ TM to add galactose to the terminal GlcNAc. At the end point of the reaction a conversion rate of 100% was achieved. The *N*-glycan fingerprint was now dominated by the galactosylated complex-type structure G2 along unprocessed Man3F (see **Figure 2C** and **Figure 3D**). Moreover, G0 was completely converted to G2 while the residual amount of the hybrid-type structure G0F-Gn (3) was also galactosylated to G1F-Gn (3). All oligomannose-type structures remained unaltered throughout the reaction. In general, the xCGE-LIF and the MALDI-TOF-MS data were in excellent agreement for all measurements.

DISCUSSION

Due to its scalability, eukaryotic protein processing and high productivity, the baculovirus-insect cell expression system is well-suited for the production of subunit vaccines (Felberbaum, 2015; Palomares et al., 2018). In addition to subunit vaccines against SARS-CoV-2 infections in development, there are currently three licensed vaccines, Flublok[®], Cervarix[®] and Provenge[®] produced using this expression system with several more in clinical trials (Felberbaum, 2015; Palomares et al., 2018).

High immunogenicity of a recombinant insect-cell produced spike protein ectodomain variant, very similar to the one used here, has been confirmed in non-human primates [40]. Moreover, the spike protein is the antigen target of virtually all COVID-19 vaccines and advanced vaccine candidates (Krammer, 2020). At the time of writing this article, there was one licensed COVID-19 protein subunit vaccine (RBD-Dimer from Anhui Zhifei Longcom Biopharmaceutical, China) in China, while for two more candidates (Covovax from Novavax, United States; VAT00002 from Sanofi Pasteur and GSK, France/United Kingdom) emergency authorization was pending in the US and Europe (Yang et al., 2020; Dai and Gao, 2021; Shrotri et al., 2021). All three are recombinant SARS-CoV-2 spike protein variants produced using the baculovirus-insect cell expression system (Kyriakidis et al., 2021).

Glycoforms of recombinant proteins produced using baculovirus-insect cell expression systems are profoundly different from those produced using mammalian expression systems. An extensive review on the glycosylation processing of insect cells is given by Geisler et al. (2015). Typically, these proteins display mainly paucimannose and hybrid-type *N*-glycans with, at most, minor fractions of complex-type and oligomannose-type *N*-glycan (Geisler et al., 2015). Moreover, in comparison to *Spodoptera frugiperda* Sf9 cells, High Five[®] *Trichoplusia ni* cells can also produce core α -1,3-fucose-linked

glycans (Palomares et al., 2018). The presence of the latter on biologics may cause hypersensitivity reactions when applied to patients with allergy and, thus, should be avoided, for instance by cell line engineering (Palmberger et al., 2014). According to the manufacturer's information the recombinant SARS-CoV-2 spike protein used here was produced in the High Five® cell line. However, we excluded core α -1,3-fucose-linked glycans from the examination by using PNGase F that does not release this type of glycans from the protein backbone (Tretter et al., 1991).

For vaccine development, it has been proposed that immunogen candidates benefit from closely mimicking the macro- and microheterogeneity of the live virus glycosylation (Grant et al., 2020; Watanabe et al., 2020). This is as eliciting antibodies against shielded or non-native epitopes could cause an inefficient immune response. To overcome such obstacles, novel strategies utilizing distinct non-human glycans containing N-glycolylneuraminic acid or α ,1-3 linked galactose residues, have been proposed to alleviate immune responses (Hütter et al., 2013; Galili, 2020; Schön et al., 2020; Chen, 2021). However, such approaches still need to be investigated in detail experimentally as, for example, both compounds are also suspected to cause allergenic reactions in humans.

To convert the glycoform from primarily paucimannose-type to typical mammalian complex-type N-glycans, the recombinant human glycosyltransferases, MGAT1 Δ TM, MGAT2 Δ TM and GalT Δ TM, were effectively combined in a cell-free, one-pot glycosylation reaction. The gene expression of these glycosyltransferases in *E. coli* and the activity of the His-tag purified, soluble recombinant proteins in one-pot reactions using free glycans as substrates has been shown before (Fujiyama et al., 2001).

The site-specific glycan analysis of recombinant SARS-CoV-2 spike protein ectodomain expressed in human-derived cell line FreeStyle™ 293-F showed that of the 22 N-glycosylation sites only eight contained substantial fractions of oligomannose-type N-glycans (Watanabe et al., 2020). It is assumed that the occurrence of oligomannose-type fractions is caused by the steric inaccessibility of these glycans to the glycan processing enzymes in the Golgi, i.e., the occurrence of oligomannose-type N-glycans at distinct sites has shown to be independent of the producer cell line for the HIV viral glycoprotein gp120 (Pritchard et al., 2015). In accordance with the human cell-derived spike protein, our engineered spike protein abundantly exhibited complex-type G2F N-glycans. To a minor extend, a range of hybrid- and oligomannose-type N-glycans were also detected on the engineered spike protein. In contrast to the engineered spike protein, human cell-derived spike proteins also exhibit complex-type multi-antennary and sialylated structures (Watanabe et al., 2020). Taken together, a significant overlap of the glycoform has been generated. Whether the overlap is also site-specific remains to be investigated in future.

Over the past years, many efforts have been made to engineer insect cell lines to express complex-type N-glycans. A comprehensive summary of the attempts is given by Palomares et al. (2018). Briefly, complex-type N-glycans can be produced by the co-expression of glycosyltransferases or by generating transient insect cell lines. While the former generates

an additional metabolic burden and affects growth properties, the stability of the latter has not been examined for commercial scale use. The advantage of *in-vitro* glycoengineering lies in its independence of producer cell lines as well as its flexibility towards the option to readily generate different glycoforms that are close to homogeneity. However, expensive nucleotides sugars are required as substrates and, thus, it is so far not feasible to apply *in-vitro* glycoengineering at larger scales (Mahour et al., 2018; Rexer et al., 2018; Rexer et al., 2020b).

CONCLUSION

SARS-CoV-2 spike glycoprotein variants produced in a baculovirus-insect cell expression system were *in-vitro* glycoengineered using recombinant glycosyltransferases to mimic the glycoform observed on the human cell-derived protein. *In-vitro* glycoengineering reactions as conducted here, can be used to generate immunogen candidates for pre-clinical testing to investigate the role of glycosylation on the antigenicity and immunogenicity in animal models. In general, *in-vitro* glycoengineering approaches can virtually be used to tailor the glycoform of all prominent vaccine candidates such as activated and attenuated viruses and virus like particles. The application of the technology to larger scales depends on the bulk availability of sugar nucleotides at moderate costs.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

JR, VG conducted the experiments and wrote experimental sections; TR conceived the study and wrote the manuscript; MJ-O, DB, RM, ER, UR contributed with intellectual input to the study and edited the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

The project is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)—Projektnummer 458633485. DB acknowledges funding from the State of Saxony-Anhalt (Förderkenzeichen I 130). ER und VG acknowledge funding by DFG- FOR2509: RA2992/1-1.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fbioe.2021.699025/full#supplementary-material>

REFERENCES

- Bagdonaite, I., and Wandall, H. H. (2018). Global Aspects of Viral Glycosylation. *Glycobiology* 28, 443–467. doi:10.1093/glycob/cwy021
- Behrens, A.-J., Vasiljevic, S., Pritchard, L. K., Harvey, D. J., Andev, R. S., Krumm, S. A., et al. (2016). Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. *Cel Rep.* 14, 2695–2706. doi:10.1016/j.celrep.2016.02.058
- Bendiak, B. (2014). “Mannosyl (Alpha-1,6-)-Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase (MGAT2),” in *Handbook of Glycosyltransferases and Related Genes*. Editors N. Taniguchi, K. Honke, M. Fukuda, H. Narimatsu, Y. Yamaguchi, and T. Angata (Tokyo: Springer Japan)), 195–207. doi:10.1007/978-4-431-54240-7_123
- Boeggeman, E. E., Ramakrishnan, B., and Qasba, P. K. (2003). The N-Terminal Stem Region of Bovine and Human β 1,4-galactosyltransferase I Increases the *In Vitro* Folding Efficiency of Their Catalytic Domain from Inclusion Bodies. *Protein Expr. Purif.* 30, 219–229. doi:10.1016/s1046-5928(03)00093-7
- Chen, J. M. (2021). SARS-CoV-2 Replicating in Nonprimate Mammalian Cells Probably Have Critical Advantages for COVID-19 Vaccines Due to anti-Gal Antibodies: A Minireview and Proposals. *J. Med. Virol.* 93, 351–356. doi:10.1002/jmv.26312
- Chen, W.-H., Du, L., Chag, S. M., Ma, C., Tricoche, N., Tao, X., et al. (2014). Yeast-expressed Recombinant Protein of the Receptor-Binding Domain in SARS-CoV Spike Protein with Deglycosylated Forms as a SARS Vaccine Candidate. *Hum. Vaccin. Immunother.* 10, 648–658. doi:10.4161/hv.27464
- Cymer, F., Beck, H., Rohde, A., and Reusch, D. (2018). Therapeutic Monoclonal Antibody N-Glycosylation - Structure, Function and Therapeutic Potential. *Biologicals* 52, 1–11. doi:10.1016/j.biologicals.2017.11.001
- Dai, L., and Gao, G. F. (2021). Viral Targets for Vaccines against COVID-19. *Nat. Rev. Immunol.* 21, 73–82. doi:10.1038/s41577-020-00480-0
- Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., and Dwek, R. A. (2014). Emerging Principles for the Therapeutic Exploitation of Glycosylation. *Science* 343, 1235681–1235688. doi:10.1126/science.1235681
- Felberbaum, R. S. (2015). The Baculovirus Expression Vector System: A Commercial Manufacturing Platform for Viral Vaccines and Gene Therapy Vectors. *Biotechnol. J.* 10, 702–714. doi:10.1002/biot.201400438
- Fischöder, T., Cajic, S., Grote, V., Heinzler, R., Reichl, U., Franzreb, M., et al. (2019). Enzymatic Cascades for Tailored 13C6 and 15N Enriched Human Milk Oligosaccharides. *Molecules* 24 (19), 3482. doi:10.3390/molecules24193482
- Francica, J. R., Varela-Rohena, A., Medvec, A., Plesa, G., Riley, J. L., and Bates, P. (2010). Steric Shielding of Surface Epitopes and Impaired Immune Recognition Induced by the Ebola Virus Glycoprotein. *Plos Pathog.* 6 (9), e1001098. doi:10.1371/journal.ppat.1001098
- Fujiyama, K., Ido, Y., Misaki, R., Moran, D. G., Yanagihara, I., Honda, T., et al. (2001). Human N-Acetylglucosaminyltransferase I. Expression in *Escherichia coli* as a Soluble Enzyme, and Application as an Immobilized Enzyme for the Chemoenzymatic Synthesis of N-Linked Oligosaccharides. *J. Biosci. Bioeng.* 92, 569–574. doi:10.1016/s1389-1723(01)80318-2
- Galili, U. (2020). Amplifying Immunogenicity of Prospective Covid-19 Vaccines by Glycoengineering the Coronavirus Glycan-Shield to Present α -gal Epitopes. *Vaccine* 38, 6487–6499. doi:10.1016/j.vaccine.2020.08.032
- Geisler, C., Mabashi-Asazuma, H., and Jarvis, D. L. (2015). An Overview and History of Glyco-Engineering in Insect Expression Systems. *Glyco-Engineering: Methods Protoc.* 1321, 131–152. doi:10.1007/978-1-4939-2760-9_10
- Go, E. P., Ding, H., Zhang, S., Ringe, R. P., Nicely, N., Hua, D., et al. (2017). Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. *J. Virol.* 91 (9), e02428–16. doi:10.1128/jvi.02428-16
- Gram, A. M., Oosenbrug, T., Lindnerbergh, M. F. S., Bull, C., Comvalius, A., Dickson, K. J. I., et al. (2016). The Epstein-Barr Virus Glycoprotein Gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells. *Plos Pathog.* 12 (4), e1005550. doi:10.1371/journal.ppat.1005550
- Grant, O. C., Montgomery, D., Ito, K., and Woods, R. J. (2020). Analysis of the SARS-CoV-2 Spike Protein Glycan Shield Reveals Implications for Immune Recognition. *Sci. Rep.* 10 (1), 1–11. doi:10.1038/s41598-020-71748-7
- Helle, F., Duverlie, G., and Dubuisson, J. (2011). The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response. *Viruses* 3, 1909–1932. doi:10.3390/v3101909
- Hennig, R., Cajic, S., Borowiak, M., Hoffmann, M., Kottler, R., Reichl, U., et al. (2016). Towards Personalized Diagnostics via Longitudinal Study of the Human Plasma N-Glycome. *Biochim. Biophys. Acta (Bba) - Gen. Subjects* 1860, 1728–1738. doi:10.1016/j.bbagen.2016.03.035
- Hennig, R., Rapp, E., Kottler, R., Cajic, S., Borowiak, M., and Reichl, U. (2015). N-glycosylation Fingerprinting of Viral Glycoproteins by xCGE-LIF. *Methods Mol. Biol.* 1331, 123–143. doi:10.1007/978-1-4939-2874-3_8
- Hütter, J., Rödig, J. V., Höper, D., Seeberger, P. H., Reichl, U., Rapp, E., et al. (2013). Toward Animal Cell Culture-Based Influenza Vaccine Design: Viral HemagglutininN-Glycosylation Markedly Impacts Immunogenicity. *J. Immunol.* 190, 220–230. doi:10.4049/jimmunol.1201060
- Imperiali, B., and O'Connor, S. E. (1999). Effect of N-Linked Glycosylation on Glycopeptide and Glycoprotein Structure. *Curr. Opin. Chem. Biol.* 3, 643–649. doi:10.1016/s1367-5931(99)00021-6
- Krammer, F. (2020). SARS-CoV-2 Vaccines in Development. *Nature* 586, 516–527. doi:10.1038/s41586-020-2798-3
- Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., and Prado, E. O. (2021). SARS-CoV-2 Vaccines Strategies: a Comprehensive Review of Phase 3 Candidates. *npj Vaccin.* 6 (1), 1–17. doi:10.1038/s41541-021-00292-w
- Li, D., Von Schaeven, M., Wang, X., Tao, W., Zhang, Y., Li, L., et al. (2016). Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice. *J. Virol.* 90, 10486–10498. doi:10.1128/jvi.01462-16
- Lin, G., Simmons, G., Pöhlmann, S., Baribaud, F., Ni, H., Leslie, G. J., et al. (2003). Differential N-Linked Glycosylation of Human Immunodeficiency Virus and Ebola Virus Envelope Glycoproteins Modulates Interactions with DC-SIGN and DC-SIGNR. *J. Virol.* 77, 1337–1346. doi:10.1128/jvi.77.2.1337-1346.2003
- Lin, S.-C., Jan, J.-T., Dionne, B., Butler, M., Huang, M.-H., Wu, C.-Y., et al. (2013). Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans. *PLOS ONE* 8, e66719. doi:10.1371/journal.pone.0066719
- Mahour, R., Klapproth, J., Rexer, T. F. T., Schildbach, A., Klamt, S., Pietzsch, M., et al. (2018). Establishment of a Five-Enzyme Cell-free cascade for the Synthesis of Uridine Diphosphate N-Acetylglucosamine. *J. Biotechnol.* 283, 120–129. doi:10.1016/j.jbiotec.2018.07.027
- Neelamegham, S., Aoki-Kinoshita, K., Bolton, E., Frank, M., Lisacek, F., Lütke, T., et al. (2019). Updates to the Symbol Nomenclature for Glycans Guidelines. *Glycobiology* 29, 620–624. doi:10.1093/glycob/cwz045
- Palmberger, D., Ashjaei, K., Strell, S., Hoffmann-Sommergruber, K., and Grabherr, R. (2014). Minimizing Fucosylation in Insect Cell-Derived Glycoproteins Reduces Binding to IgE Antibodies from the Sera of Patients with Allergy. *Biotechnol. J.* 9, 1206–1214. doi:10.1002/biot.201400061
- Palomares, L. A., Srivastava, I. K., Ramirez, O. T., and Cox, M. M. J. (2018). Glycobiotechnology of the Insect Cell-Baculovirus Expression System Technology. *Adv. Biochem. Engineering/Biotechnology*, 1–22. doi:10.1007/10_2018_61
- Pralow, A., Hoffmann, M., Nguyen-Khuong, T., Pioch, M., Hennig, R., Genzel, Y., et al. (2021). Comprehensive N-Glycosylation Analysis of the Influenza A Virus Proteins HA and NA from Adherent and Suspension MDCK Cells. *FEBS J* [Epub ahead of print]. doi:10.1111/febs.15787
- Pritchard, L. K., Harvey, D. J., Bonomelli, C., Crispin, M., and Doores, K. J. (2015). Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. *J. Virol.* 89, 8932–8944. doi:10.1128/jvi.01190-15
- Ramakrishnan, B., and Qasba, P. K. (2014). “UDP-gal: BetaGlcNAc Beta 1,4-Galactosyltransferase, Polypeptide 1 (B4GALT1),” in *Handbook of Glycosyltransferases and Related Genes*. Editors N. Taniguchi, K. Honke, M. Fukuda, H. Narimatsu, Y. Yamaguchi, and T. Angata (Tokyo: Springer), 51–62. doi:10.1007/978-4-431-54240-7_110
- Rexer, T. F. T., Laaf, D., Gottschalk, J., Frohnmeyer, J., Rapp, E., and Elling, L. (2020a). “Enzymatic Synthesis of Glycans and Glycoconjugates,” in *Advances in Glycobiotechnology*. Editors E. Rapp and U. Reichl (Berlin: Springer), 1–50. doi:10.1007/10_2020_159
- Rexer, T. F. T., Schildbach, A., Klapproth, J., Schierhorn, A., Mahour, R., Pietzsch, M., et al. (2018). One Pot Synthesis of GDP-Mannose by a Multi-Enzyme

- cascade for Enzymatic Assembly of Lipid-Linked Oligosaccharides. *Biotechnol. Bioeng.* 115, 192–205. doi:10.1002/bit.26454
- Rexer, T. F. T., Wenzel, L., Hoffmann, M., Tischlik, S., Bergmann, C., Grote, V., et al. (2020b). Synthesis of Lipid-Linked Oligosaccharides by a Compartmentalized Multi-Enzyme cascade for the *In Vitro* N-Glycosylation of Peptides. *J. Biotechnol.* 322, 54–65. doi:10.1016/j.jbiotec.2020.07.003
- Rödiger, J., Rapp, E., Djeljadini, S., Lohr, V., Genzel, Y., Jordan, I., et al. (2011). Impact of Influenza Virus Adaptation Status on HAN-Glycosylation Patterns in Cell Culture-Based Vaccine Production. *J. Carbohydr. Chem.* 30, 281–290. doi:10.1080/07328303.2011.604454
- Rödiger, J. V., Rapp, E., Bohne, J., Kampe, M., Kaffka, H., Bock, A., et al. (2013). Impact of Cultivation Conditions on N-Glycosylation of Influenza Virus a Hemagglutinin Produced in MDCK Cell Culture. *Biotechnol. Bioeng.* 110, 1691–1703. doi:10.1002/bit.24834
- Schön, K., Lepenies, B., and Goyette-Desjardins, G. (2020). Impact of Protein Glycosylation on the Design of Viral Vaccines. *Adv. Biochem. Engineering/Biotechnology*, 1–36. doi:10.1007/10_2020_132
- Schwarzer, J., Rapp, E., Hennig, R., Genzel, Y., Jordan, I., Sandig, V., et al. (2009). Glycan Analysis in Cell Culture-Based Influenza Vaccine Production: Influence of Host Cell Line and Virus Strain on the Glycosylation Pattern of Viral Hemagglutinin. *Vaccine* 27, 4325–4336. doi:10.1016/j.vaccine.2009.04.076
- Selman, M. H. J., Hemayatkar, M., Deelder, A. M., and Wuhler, M. (2011). Cotton HILIC SPE Microtips for Microscale Purification and Enrichment of Glycans and Glycopeptides. *Anal. Chem.* 83, 2492–2499. doi:10.1021/ac1027116
- Shrotri, M., Swinnen, T., Kampmann, B., and Parker, E. P. K. (2021). An Interactive Website Tracking COVID-19 Vaccine Development. *Lancet Glob. Health* 9 (5), e590–e592. doi:10.1016/s2214-109x(21)00043-7
- Sommerstein, R., Flatz, L., Remy, M. M., Malinge, P., Magistrelli, G., Fischer, N., et al. (2015). Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. *Plos Pathog.* 11 (11), e1005276. doi:10.1371/journal.ppat.1005276
- Stanley, P. (2014). Mannosyl (Alpha-1,3-)- Glycoprotein Beta-1,2-N-Acetylglucosaminyltransferase (MGAT1). *Handbook of Glycosyltransferases and Related Genes*. Second Edition (Tokyo: Springer), 183–194. doi:10.1007/978-4-431-54240-7_129
- Stanley, P., Taniguchi, N., and Aebi, M. (2015). “N-glycans,” in *Essentials of Glycobiology*. Editors A. Varki, R. D. Cummings, J. D. Esko, P. Stanley, G. W. Hart, M. Aebi, et al. (NY: Cold Spring Harbor Laboratory Press), 99–111.
- Tretter, V., Altmann, F., and März, L. (1991). Peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine Amidase F Cannot Release Glycans with Fucose Attached Alpha 3 to the Asparagine-Linked N-Acetylglucosamine Residue. *Eur. J. Biochem.* 199, 647–652. doi:10.1111/j.1432-1033.1991.tb16166.x
- Tsuchiya, S., Aoki, N. P., Shinmachi, D., Matsubara, M., Yamada, I., Aoki-Kinoshita, K. F., et al. (2017). Implementation of GlycanBuilder to Draw a Wide Variety of Ambiguous Glycans. *Carbohydr. Res.* 445, 104–116. doi:10.1016/j.carres.2017.04.015
- Van Landuyt, L., Lonigro, C., Meuris, L., and Callewaert, N. (2019). Customized Protein Glycosylation to Improve Biopharmaceutical Function and Targeting. *Curr. Opin. Biotechnol.* 60, 17–28. doi:10.1016/j.copbio.2018.11.017
- Varki, A. (2017). Biological Roles of Glycans. *Glycobiology* 27, 3–49. doi:10.1093/glycob/cww086
- Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., and Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 181, 281–292. doi:10.1016/j.cell.2020.02.058
- Walls, A. C., Tortorici, M. A., Frenz, B., Snijder, J., Li, W., Rey, F. A., et al. (2016). Glycan Shield and Epitope Masking of a Coronavirus Spike Protein Observed by Cryo-Electron Microscopy. *Nat. Struct. Mol. Biol.* 23, 899–905. doi:10.1038/nsmb.3293
- Wan, Y., Shang, J., Graham, R., Baric, R. S., and Li, F. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J. Virol.* 94 (7), e00127–20. doi:10.1128/jvi.00127-20
- Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., and Crispin, M. (2020). Site-specific Glycan Analysis of the SARS-CoV-2 Spike. *Science* 369, 330–333. doi:10.1126/science.abb9983
- Watanabe, Y., Bowden, T. A., Wilson, I. A., and Crispin, M. (2019). Exploitation of Glycosylation in Enveloped Virus Pathobiology. *Biochim. Biophys. Acta (Bba) - Gen. Subjects* 1863, 1480–1497. doi:10.1016/j.bbagen.2019.05.012
- Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., et al. (2020). Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *Science* 367, 1260–1263. doi:10.1126/science.abb2507
- Yang, J., Wang, W., Chen, Z., Lu, S., Yang, F., Bi, Z., et al. (2020). A Vaccine Targeting the RBD of the S Protein of SARS-CoV-2 Induces Protective Immunity. *Nature* 586, 572–577. doi:10.1038/s41586-020-2599-8
- Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., et al. (2020). A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. *Nature* 579, 270–273. doi:10.1038/s41586-020-2012-7

Conflict of Interest: ER and UR hold shares in glyXera GmbH.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Ruhnau, Grote, Juarez-Osorio, Bruder, Mahour, Rapp, Rexer and Reichl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.